Cas:194242-26-7 3-Methoxybenzylhydrazinedihydrochloride manufacturer & supplier

Chemical Name:3-Methoxybenzylhydrazinedihydrochloride

CAS.NO:194242-26-7

Synonyms:3-Methoxybenzylhydrazinedihydrochloride

Molecular Formula:C₈H₁₄Cl₂N₂O

Molecular Weight:225.11600

HS Code:

Physical and Chemical Properties:

Melting point:116-118ºC

Boiling point:311.4ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:47.28000

Exact Mass:224.04800

LogP:3.35370

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Methoxybenzylhydrazinedihydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methoxybenzylhydrazinedihydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Methoxybenzylhydrazinedihydrochloride Use and application,3-Methoxybenzylhydrazinedihydrochloride technical grade,usp/ep/jp grade.

Related News: Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities. 3-Methoxybenzylhydrazinedihydrochloride manufacturer Under the strict supervision of environmental protection, it has helped the API industry to continuously optimize its product structure, realize industrial upgrading, and transition to the development of high-end APIs. 3-Methoxybenzylhydrazinedihydrochloride supplier Under the strict supervision of environmental protection, it has helped the API industry to continuously optimize its product structure, realize industrial upgrading, and transition to the development of high-end APIs. 3-Methoxybenzylhydrazinedihydrochloride vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 3-Methoxybenzylhydrazinedihydrochloride factory Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.